Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where Private Medtech Investments Dollars Went in 2010

This article was originally published in Start Up

Executive Summary

Overall in 2010, caution was the watchword for private investors, placing fewer dollars in fewer medtech deals compared to 2009. A total of $1.86 billion in private money was raised by medical device companies in 2010, a big drop from the $2.86 billion placed in the industry in 2009. Deal volume was down commensurately; there were 139 private medical device financings, compared to 207 in 2009. Investment dollars were apportioned, for the most part, in the usual fashion, with the largest proportion going into cardiovascular deals, followed by orthopedics. There were some surprises however, as a few categories, once avoided like the plaque, showed new investor interest.

You may also be interested in...



Noninvasive Body Contouring Begins To Take Shape

Noninvasive body contouring is the hottest new trend in aesthetics. The concept of losing fat without surgery is both appealing and promising to patients, aesthetic physicians, investors and medical device manufacturers alike, and industry has been quick to respond. In this issue, we profile three device start-ups that hope to gain footing in this lucrative market.

TCT 2010: TAVI Takes Center Stage

In the interventional cardiology community, 2010 could certainly be considered a breakthrough year for percutaneous heart valve devices. At two major US cardiology conferences: the American College of Cardiology in the spring, and most recently, the Transcatheter Cardiovascular Therapeutics symposium, held in September, impressive results from randomized trials of transcatheter heart valve replacement/repair devices set the venues abuzz and had physicians speculating about possible near-term paradigm shifts in the way heart valve disease will be treated. The big questions now are how long it will take before these devices reach the US market, and exactly how many US patients are likely to be implanted once they are available.

TriVascular's Sequel Could Be a Blockbuster

When Boston Scientific shut down TriVascular all appeared to be lost for the one-time hard-charging start-up that took on the daunting abdominal aortic aneurysm market. But TriVascular’s core investors and evangelical executive team have given the company new life.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel